SCHEMBL6577939

SCHEMBL6577939

CC(C)(C)OC(=O)NCCc1c[nH]c2ccc(S(=O)(=O)c3ccccc3)cc12

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.53
SPR P35270 1/20 0.53
TRPV1 Q8NER1 2/20 0.51
LTA4H P09960 2/20 0.50
PLA2G2A P14555 2/20 0.50
TRPM8 Q7Z2W7 1/20 0.49
IDO1 P14902 1/20 0.49
MAPT P10636 2/20 0.49
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
MTNR1A P48039 3/20 0.48
MTNR1B P49286 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NQO2 P16083 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6577932 0.92 MTNR1A (0.54) FAAHSPRTRPV1MAPTALDH1A1
SCHEMBL7334188 0.83 TRPV1 (0.65) FAAHTRPV1LTA4HPLA2G2ATRPM8
SCHEMBL5745010 0.81 MEN1 (0.67) FAAHMTNR1AMEN1KMT2APOLB
SCHEMBL6575604 0.81 MTNR1A (0.47) SPRMAPTMTNR1AMTNR1BMEN1
SCHEMBL8807970 0.81 HTR7 (0.57) FAAHSPRTRPV1IDO1MAPT
SCHEMBL8613795 0.81 TRPV1 (0.55) FAAHSPRTRPV1IDO1MAPT
SCHEMBL798165 0.81 TRPV1 (0.70) SPRTRPV1IDO1MAPTALDH1A1
SCHEMBL31077788 0.81 TRPV1 (0.70) SPRTRPV1IDO1MAPTALDH1A1
SCHEMBL2544150 0.80 HPGD (0.55) FAAHSPRTRPV1IDO1MAPT
SCHEMBL7318352 0.80 MTNR1A (0.70) FAAHSPRTRPV1TRPM8IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1411925-A1 5-ARYLSULFONYL INDOLES HAVING 5-HT6 RECEPTOR AFFINITY PHARMACIA & UPJOHN COMPANY (US) 2004-04-28 EP claimed
US-6565829-B2 Psychological disorders; central nervous system disorders PHARMACIA & UPJOHN COMPANY 2003-05-20 US claimed
US-20030060498-A1 5-arylsulfonyl indoles useful for treating disease PHARMACIA & UPJOHN COMPANY 2003-03-27 US claimed
WO-2003011284-A1 5-ARYLSULFONYL INDOLES HAVING 5-HT6 RECEPTOR AFFINITY PHARMACIA & UPJOHN COMPANY (US) 2003-02-13 WO claimed
EP-1411925-A1 5-ARYLSULFONYL INDOLES HAVING 5-HT6 RECEPTOR AFFINITY PHARMACIA & UPJOHN COMPANY (US) 2004-04-28 EP disclosed
US-6565829-B2 Psychological disorders; central nervous system disorders PHARMACIA & UPJOHN COMPANY 2003-05-20 US disclosed
US-20030060498-A1 5-arylsulfonyl indoles useful for treating disease PHARMACIA & UPJOHN COMPANY 2003-03-27 US disclosed
WO-2003011284-A1 5-ARYLSULFONYL INDOLES HAVING 5-HT6 RECEPTOR AFFINITY PHARMACIA & UPJOHN COMPANY (US) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060498-A1 5-arylsulfonyl indoles useful for treating disease IDO1, HTR5A, IDO2 FAAH 675/4885SPR 807/4885TRPV1 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.